297 related articles for article (PubMed ID: 24783461)
1. Increased cardiovascular risk in patients with rheumatoid arthritis: an overview.
Puttevils D; De Vusser P; Geusens P; Dens J
Acta Cardiol; 2014 Apr; 69(2):111-8. PubMed ID: 24783461
[TBL] [Abstract][Full Text] [Related]
2. Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy.
Galarraga B; Belch JJ; Pullar T; Ogston S; Khan F
J Rheumatol; 2010 Mar; 37(3):521-8. PubMed ID: 20080919
[TBL] [Abstract][Full Text] [Related]
3. Relations of serum COMP to cardiovascular risk factors and endothelial function in patients with rheumatoid arthritis treated with methotrexate and TNF-α inhibitors.
Hjeltnes G; Hollan I; Førre Ø; Wiik A; Lyberg T; Mikkelsen K; Agewall S
J Rheumatol; 2012 Jul; 39(7):1341-7. PubMed ID: 22660798
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular risk in rheumatoid arthritis.
Nurmohamed MT
Autoimmun Rev; 2009 Jul; 8(8):663-7. PubMed ID: 19393192
[TBL] [Abstract][Full Text] [Related]
5. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
Roubille C; Richer V; Starnino T; McCourt C; McFarlane A; Fleming P; Siu S; Kraft J; Lynde C; Pope J; Gulliver W; Keeling S; Dutz J; Bessette L; Bissonnette R; Haraoui B
Ann Rheum Dis; 2015 Mar; 74(3):480-9. PubMed ID: 25561362
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular risk in rheumatoid arthritis: how to lower the risk?
van Breukelen-van der Stoep DF; Klop B; van Zeben D; Hazes JM; Castro Cabezas M
Atherosclerosis; 2013 Nov; 231(1):163-72. PubMed ID: 24125429
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular disease in the QUEST-RA study, 10 years later.
Naranjo A; Ferraz-Amaro I
Arthritis Res Ther; 2019 Nov; 21(1):242. PubMed ID: 31727147
[No Abstract] [Full Text] [Related]
8. Cardiovascular disease in rheumatoid arthritis.
Gonzalez-Gay MA; Gonzalez-Juanatey C; Miranda-Filloy JA; Garcia-Porrua C; Llorca J; Martin J
Biomed Pharmacother; 2006 Dec; 60(10):673-7. PubMed ID: 17049201
[TBL] [Abstract][Full Text] [Related]
9. Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis.
Kerekes G; Soltész P; Dér H; Veres K; Szabó Z; Végvári A; Shoenfeld Y; Szekanecz Z
Ann N Y Acad Sci; 2009 Sep; 1173():814-21. PubMed ID: 19758233
[TBL] [Abstract][Full Text] [Related]
10. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.
Greenberg JD; Kremer JM; Curtis JR; Hochberg MC; Reed G; Tsao P; Farkouh ME; Nasir A; Setoguchi S; Solomon DH;
Ann Rheum Dis; 2011 Apr; 70(4):576-82. PubMed ID: 21109516
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular safety of biologic therapies for the treatment of RA.
Greenberg JD; Furer V; Farkouh ME
Nat Rev Rheumatol; 2011 Nov; 8(1):13-21. PubMed ID: 22083220
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs.
Avouac J; Allanore Y
Expert Opin Pharmacother; 2008 May; 9(7):1121-8. PubMed ID: 18422470
[TBL] [Abstract][Full Text] [Related]
13. [Rheumatoid arthritis: a cardiovascular disease?].
Daïen CI; Fesler P
Ann Cardiol Angeiol (Paris); 2012 Apr; 61(2):111-7. PubMed ID: 21885031
[TBL] [Abstract][Full Text] [Related]
14. Rheumatoid arthritis and cardiovascular disease: an update on treatment issues.
Barbhaiya M; Solomon DH
Curr Opin Rheumatol; 2013 May; 25(3):317-24. PubMed ID: 23466960
[TBL] [Abstract][Full Text] [Related]
15. What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology.
Dixon WG; Symmons DP
Ann Rheum Dis; 2007 Sep; 66(9):1132-6. PubMed ID: 17251223
[TBL] [Abstract][Full Text] [Related]
16. Reducing the cardiovascular disease burden in rheumatoid arthritis.
Van Doornum S; Jennings GL; Wicks IP
Med J Aust; 2006 Mar; 184(6):287-90. PubMed ID: 16548834
[TBL] [Abstract][Full Text] [Related]
17. Will antirheumatic treatment improve cardiovascular outcomes in patients with rheumatoid arthritis?
Pieringer H; Pichler M; Pohanka E; Hoppe UC
Curr Pharm Des; 2014; 20(4):486-95. PubMed ID: 23565635
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular risk in rheumatoid arthritis.
Soubrier M; Barber Chamoux N; Tatar Z; Couderc M; Dubost JJ; Mathieu S
Joint Bone Spine; 2014 Jul; 81(4):298-302. PubMed ID: 24880190
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs.
Solomon DH; Curtis JR; Saag KG; Lii J; Chen L; Harrold LR; Herrinton LJ; Graham DJ; Kowal MK; Kuriya B; Liu L; Griffin MR; Lewis JD; Rassen JA
Am J Med; 2013 Aug; 126(8):730.e9-730.e17. PubMed ID: 23885678
[TBL] [Abstract][Full Text] [Related]
20. Potential effect of anti-tumour necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis.
Cugno M; Ingegnoli F; Gualtierotti R; Fantini F
Curr Vasc Pharmacol; 2010 Mar; 8(2):285-92. PubMed ID: 19485909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
